|
| Index | - | P/E | - | EPS (ttm) | -1.89 | Insider Own | 0.70% | Shs Outstand | 26.24M | Perf Week | -10.82% |
| Market Cap | 81.14M | Forward P/E | - | EPS next Y | -1.82 | Insider Trans | 0.00% | Shs Float | 17.75M | Perf Month | 0.00% |
| Income | -45.50M | PEG | - | EPS next Q | -0.41 | Inst Own | 66.00% | Short Float | 4.26% | Perf Quarter | -58.61% |
| Sales | - | P/S | - | EPS this Y | -368.80% | Inst Trans | 0.81% | Short Ratio | 3.43 | Perf Half Y | -66.92% |
| Book/sh | 5.91 | P/B | 0.59 | EPS next Y | -11.80% | ROA | -29.10% | Target Price | 24.00 | Perf Year | - |
| Cash/sh | 5.28 | P/C | 0.65 | EPS next 5Y | - | ROE | -40.70% | 52W Range | 2.52 - 29.69 | Perf YTD | -66.92% |
| Dividend | - | P/FCF | - | EPS past 5Y | - | ROI | - | 52W High | -88.51% | Beta | - |
| Dividend % | - | Quick Ratio | 19.30 | Sales past 5Y | - | Gross Margin | - | 52W Low | 35.32% | ATR | 0.55 |
| Employees | 37 | Current Ratio | 19.30 | Sales Q/Q | - | Oper. Margin | - | RSI (14) | 44.15 | Volatility | 15.41% 15.85% |
| Optionable | No | Debt/Eq | 0.00 | EPS Q/Q | 35.20% | Profit Margin | - | Rel Volume | 0.02 | Prev Close | 3.46 |
| Shortable | Yes | LT Debt/Eq | 0.00 | Earnings | May 16 BMO | Payout | - | Avg Volume | 220.19K | Price | 3.41 |
| Recom | 1.70 | SMA20 | -14.28% | SMA50 | -8.47% | SMA200 | -65.90% | Volume | 3,019 | Change | -1.45% |
 |
|
|
| ||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||
| Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase IIa clinical trial; and ETX-155 for the treatment of major depressive disorder, perimenopausal depression, and focal onset seizures that is in Phase I clinical trial. The company also develops preclinical pipeline programs, such as Kv7 Program for pain, epilepsy, and depression; and Anxiolytic for the treatment of generalized anxiety disorder. Eliem Therapeutics, Inc. was incorporated in 2018 and is headquartered in Redmond, Washington. | ||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||
|
| open in yahoo | open in reuters | open in marketwatch | open in google |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite